Taiwan's biotechnology industry is poised to cash in on drugs developed from traditional Chinese herbal remedies, experts said yesterday.
"In Taiwan, we are doing good research in Chinese herbal rem-edies, but now we need to commercialize," Winston Town (湯竣鈞), chief operating officer of herbal drug developer Cathay Biotech Co (中華公明生物科技), told the Taipei Times yesterday.
In order to turn research investments into big bucks, companies have to prove scientifically that Chinese herbal remedies work, and the only way to do that is to present them for approval to regulatory authorities in the US, Europe and Japan, Town said.
Taiwan is banking on biotechnology and other advanced industries to replace manufacturing that has now moved to low-cost China.
In May of last year, President Chen Shui-bian (
Exploiting the nation's cultural heritage could help biotech companies to produce their own uniquely Chinese drugs.
"Traditional Chinese medicine offers excellent opportunities for Taiwanese biotechnology companies," said Jerry Chen (
Only last Friday Chen's office hosted a business opportunities forum for companies interested in developing drugs from Chinese herbs, and over 100 people attended, Chen said.
The government has funded three research centers to look specifically at herb-based drugs, the Development Center for Biotechnology in Taipei, the Pharmaceutical Industry Technology and Development Center in Taipei County and the Biomedical Engineering Center at the Industrial Technology Research Institute in Hsinchu.
But research is not enough.
"There is a huge amount of potential for Taiwanese companies through herbal medicine," said David Silver, director of Biotech-east.com, a Web site that promotes Taiwan's biotechnology and pharmaceutical industries. "But there are problems with patentability and regulations."
Companies cannot claim a patent on naturally occurring plants, but they can patent an effective chemical compound extracted from a plant that they have isolated, or present a mixture of herbs to regulatory authorities in the US, Europe and Japan and ask for approval.
To do this, they need to have carried out quality control tests and be able to guarantee consistent dosages, Silver said.
Isolating one compound in an herb is a very difficult process that involves a lot of computing power and time, Silver said, but it is very lucrative if successful. Presenting an herbal mix for approval is much simpler, and is now possible after US Food and Drug Administration rules were changed last year.
That is exactly what Cathay is doing with a mixture of 15 different Chinese herbs that it claims from its own preliminary trials can treat sufferers of Hepatitis B and HIV.
On the strength of this research, Cathay submitted an application to the FDA for its multi-herb treatment and had it accepted, Town said yesterday.
Town expects the second phase of clinical trials to be completed and approved within 12 months. After that, Cathay can sell licenses for its treatment to global pharmaceutical companies who have the resources to complete the third and final phase of trials before marketing the drug globally.
Other Taiwanese companies could follow this route.
"Our business model works," Cathay's chairman, David Wu (
While awaiting FDA approval Cathay is exploring other avenues, Wu added. In Taiwan, Cathay's approved over-the-counter liver tonic, called YGK (
If successful, the drug would be paid for by international humanitarian donations.
WASHINGTON’S INCENTIVES: The CHIPS Act set aside US$39 billion in direct grants to persuade the world’s top semiconductor companies to make chips on US soil The US plans to award more than US$6 billion to Samsung Electronics Co, helping the chipmaker expand beyond a project in Texas it has already announced, people familiar with the matter said. The money from the 2022 CHIPS and Science Act would be one of several major awards that the US Department of Commerce is expected to announce in the coming weeks, including a grant of more than US$5 billion to Samsung’s rival, Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), people familiar with the plans said. The people spoke on condition of anonymity in advance of the official announcements. The federal funding for
HIGH DEMAND: The firm has strong capabilities of providing key components including liquid cooling technology needed for AI servers, chairman Young Liu said Hon Hai Precision Industry Co (鴻海精密) yesterday revised its revenue outlook for this year to “significant” growth from a “neutral” view forecast five months ago, due to strong demand for artificial intelligence (AI) servers from cloud service providers. Hon Hai, a major assembler of iPhones that is also known as Foxconn, expects AI server revenues to soar more than 40 percent annually this year, chairman Young Liu (劉揚偉) told investors. The robust growth would uplift revenue contribution from AI servers to 40 percent of the company’s overall server revenue this year, from 30 percent last year, Liu said. In the three-year period
LONG HAUL: Largan Energy Materials’ TNO-based lithium-ion batteries are expected to charge in five minutes and last about 20 years, far surpassing conventional technology Largan Precision Co (大立光) has formed a joint venture with the Industrial Technology Research Institute (ITRI, 工研院) to produce fast-charging, long-life lithium-ion batteries for electric vehicles, mobile electronics and electric storage units, the camera lens supplier for Apple Inc’s iPhones said yesterday. Largan Energy Materials Co (萬溢能源材料), established in January, is developing high-energy, fast-charging, long-life lithium-ion batteries using titanium niobium oxide (TNO) anodes, it said. TNO-based batteries can be fully charged in five minutes and have a lifespan of 20 years, a major advantage over the two to four hours of charging time needed for conventional graphite-anode-based batteries, Largan said in a
Taiwan is one of the first countries to benefit from the artificial intelligence (AI) boom, but because that is largely down to a single company it also represents a risk, former Google Taiwan managing director Chien Lee-feng (簡立峰) said at an AI forum in Taipei yesterday. Speaking at the forum on how generative AI can generate possibilities for all walks of life, Chien said Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) — currently among the world’s 10 most-valuable companies due to continued optimism about AI — ensures Taiwan is one of the economies to benefit most from AI. “This is because AI is